Header Logo
Last Name

Priyabrata Mukherjee

InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentStephenson Cancer Center
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of Burdwan, INDIAMSc1994Chemistry
    University of Poona, INDIAPhD2000Chemistry
    Texas Christian University, Fort Worth, TXPostdoc2003Chemistry
    Harvard Medical School, Boston, MAFellow2004Chemistry
    Mayo Clinic, Rochester, MNFellow2005Research

    Collapse Research 
    Collapse research activities and funding
    R01CA220237     (MUKHERJEE, PRIYABRATA)May 1, 2018 - Apr 30, 2023
    UBAP2, A New Molecule in Pancreatic Cancer Progression
    Role: Principal Investigator

    R01CA213278     (MUKHERJEE, PRIYABRATA)Dec 22, 2016 - Nov 30, 2021
    Reprogramming Tumor Microenvironment by Nanoparticle
    Role: Principal Investigator

    R01HL120585     (MUKHERJEE, PRIYABRATA)Aug 15, 2013 - Jun 30, 2018
    Cystathionine beta synthase (CBS) and angiogenesis
    Role: Principal Investigator

    R01CA136494     (MUKHERJEE, PRIYABRATA)Dec 1, 2008 - Nov 30, 2020
    Molecular Mechanism of Antiangiogenic Properties of Gold Nanoparticle
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Prabhudesai S, Koceja C, Dey A, Eisa-Beygi S, Leigh NR, Bhattacharya R, Mukherjee P, Ramchandran R. Corrigendum: Cystathionine ß-Synthase Is Necessary for Axis Development in vivo. Front Cell Dev Biol. 2018; 6:121. PMID: 30310813.
      View in: PubMed
    2. Buechel M, Dey A, Dwivedi SKD, Crim A, Ding K, Zhang R, Mukherjee P, Moore KN, Cao L, Branstrom A, Weetall M, Baird J, Bhattacharya R. Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Mol Cancer Ther. 2018 Oct; 17(10):2136-2143. PMID: 30026381.
      View in: PubMed
    3. Hossen MN, Murphy B, Garci A-Hevia L, Bhattacharya R, Mukherjee P. Probing Cellular Processes Using Engineered Nanoparticles. Bioconjug Chem. 2018 Jun 20; 29(6):1793-1808. PMID: 29742344.
      View in: PubMed
    4. Chakraborty PK, Murphy B, Mustafi SB, Dey A, Xiong X, Rao G, Naz S, Zhang M, Yang D, Dhanasekaran DN, Bhattacharya R, Mukherjee P. Cystathionine ß-synthase regulates mitochondrial morphogenesis in ovarian cancer. FASEB J. 2018 08; 32(8):4145-4157. PMID: 29494264.
      View in: PubMed
    5. Prabhudesai S, Koceja C, Dey A, Eisa-Beygi S, Leigh NR, Bhattacharya R, Mukherjee P, Ramchandran R. Cystathionine ß-Synthase Is Necessary for Axis Development in Vivo. Front Cell Dev Biol. 2018; 6:14. PMID: 29503817.
      View in: PubMed
    6. Ha JH, Radhakrishnan R, Jayaraman M, Yan M, Ward JD, Fung KM, Moxley K, Sood AK, Isidoro C, Mukherjee P, Song YS, Dhanasekaran DN. LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Res. 2018 Apr 15; 78(8):1923-1934. PMID: 29386184.
      View in: PubMed
    7. Dey A, Xiong X, Crim A, Dwivedi SKD, Mustafi SB, Mukherjee P, Cao L, Sydorenko N, Baiazitov R, Moon YC, Dumble M, Davis T, Bhattacharya R. Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther. 2018 01; 17(1):39-49. PMID: 29158468.
      View in: PubMed
    8. Chakraborty PK, Mustafi SB, Xiong X, Dwivedi SKD, Nesin V, Saha S, Zhang M, Dhanasekaran D, Jayaraman M, Mannel R, Moore K, McMeekin S, Yang D, Zuna R, Ding K, Tsiokas L, Bhattacharya R, Mukherjee P. MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 05 22; 8:14634. PMID: 28530221.
      View in: PubMed
    9. Banerjee Mustafi S, Chakraborty PK, Dwivedi SK, Ding K, Moxley KM, Mukherjee P, Bhattacharya R. BMI1, a new target of CK2a. Mol Cancer. 2017 03 07; 16(1):56. PMID: 28270146.
      View in: PubMed
    10. Ha JH, Yan M, Gomathinayagam R, Jayaraman M, Husain S, Liu J, Mukherjee P, Reddy EP, Song YS, Dhanasekaran DN. Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer. Oncotarget. 2016 Nov 08; 7(45):72845-72859. PMID: 27655714.
      View in: PubMed
    11. Saha S, Xiong X, Chakraborty PK, Shameer K, Arvizo RR, Kudgus RA, Dwivedi SK, Hossen MN, Gillies EM, Robertson JD, Dudley JT, Urrutia RA, Postier RG, Bhattacharya R, Mukherjee P. Gold Nanoparticle Reprograms Pancreatic Tumor Microenvironment and Inhibits Tumor Growth. ACS Nano. 2016 12 27; 10(12):10636-10651. PMID: 27758098.
      View in: PubMed
    12. Banerjee Mustafi S, Aznar N, Dwivedi SK, Chakraborty PK, Basak R, Mukherjee P, Ghosh P, Bhattacharya R. Mitochondrial BMI1 maintains bioenergetic homeostasis in cells. FASEB J. 2016 12; 30(12):4042-4055. PMID: 27613804.
      View in: PubMed
    13. Banerjee Mustafi S, Chakraborty PK, Naz S, Dwivedi SK, Street M, Basak R, Yang D, Ding K, Mukherjee P, Bhattacharya R. MDR1 mediated chemoresistance: BMI1 and TIP60 in action. Biochim Biophys Acta. 2016 08; 1859(8):983-93. PMID: 27295567; PMCID: PMC4958591 [Available on 08/01/17].
    14. Dwivedi SK, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P, Calin GA, Lopez-Berestein G, Sood AK, Bhattacharya R. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):15093-104. PMID: 26918603; PMCID: PMC4924772.
    15. Giri K, Pabelick CM, Mukherjee P, Prakash YS. Hepatoma derived growth factor (HDGF) dynamics in ovarian cancer cells. Apoptosis. 2016 Mar; 21(3):329-39. PMID: 26612514.
      View in: PubMed
    16. Dey A, Mustafi SB, Saha S, Kumar Dhar Dwivedi S, Mukherjee P, Bhattacharya R. Inhibition of BMI1 induces autophagy-mediated necroptosis. Autophagy. 2016; 12(4):659-70. PMID: 27050456; PMCID: PMC4836029 [Available on 04/06/17].
    17. Chakraborty PK, Xiong X, Mustafi SB, Saha S, Dhanasekaran D, Mandal NA, McMeekin S, Bhattacharya R, Mukherjee P. Role of cystathionine beta synthase in lipid metabolism in ovarian cancer. Oncotarget. 2015 Nov 10; 6(35):37367-84. PMID: 26452259; PMCID: PMC4741935.
    18. Saha S, Chakraborty PK, Xiong X, Dwivedi SK, Mustafi SB, Leigh NR, Ramchandran R, Mukherjee P, Bhattacharya R. Cystathionine ß-synthase regulates endothelial function via protein S-sulfhydration. FASEB J. 2016 Jan; 30(1):441-56. PMID: 26405298; PMCID: PMC4684530 [Available on 01/01/17].
    19. Xiong X, Arvizo RR, Saha S, Robertson DJ, McMeekin S, Bhattacharya R, Mukherjee P. Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget. 2014 Aug 15; 5(15):6453-65. PMID: 25071019; PMCID: PMC4171643.
    20. Giri K, Shameer K, Zimmermann MT, Saha S, Chakraborty PK, Sharma A, Arvizo RR, Madden BJ, Mccormick DJ, Kocher JP, Bhattacharya R, Mukherjee P. Understanding protein-nanoparticle interaction: a new gateway to disease therapeutics. Bioconjug Chem. 2014 Jun 18; 25(6):1078-90. PMID: 24831101; PMCID: PMC4128259.
    21. Bhattacharyya S, Saha S, Giri K, Lanza IR, Nair KS, Jennings NB, Rodriguez-Aguayo C, Lopez-Berestein G, Basal E, Weaver AL, Visscher DW, Cliby W, Sood AK, Bhattacharya R, Mukherjee P. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One. 2013; 8(11):e79167. PMID: 24236104; PMCID: PMC3827285.
    22. Arvizo RR, Moyano DF, Saha S, Thompson MA, Bhattacharya R, Rotello VM, Prakash YS, Mukherjee P. Probing novel roles of the mitochondrial uniporter in ovarian cancer cells using nanoparticles. J Biol Chem. 2013 Jun 14; 288(24):17610-8. PMID: 23615904; PMCID: PMC3682561.
    23. Arvizo RR, Saha S, Wang E, Robertson JD, Bhattacharya R, Mukherjee P. Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. Proc Natl Acad Sci U S A. 2013 Apr 23; 110(17):6700-5. PMID: 23569259; PMCID: PMC3637766.
    24. Kudgus RA, Szabolcs A, Khan JA, Walden CA, Reid JM, Robertson JD, Bhattacharya R, Mukherjee P. Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. PLoS One. 2013; 8(3):e57522. PMID: 23483913; PMCID: PMC3590245.
    25. Arvizo RR, Giri K, Moyano D, Miranda OR, Madden B, McCormick DJ, Bhattacharya R, Rotello VM, Kocher JP, Mukherjee P. Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS One. 2012; 7(3):e33650. PMID: 22442705; PMCID: PMC3307759.
    26. Arvizo RR, Bhattacharyya S, Kudgus RA, Giri K, Bhattacharya R, Mukherjee P. Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem Soc Rev. 2012 Apr 07; 41(7):2943-70. PMID: 22388295; PMCID: PMC3346960.
    27. Bhattacharyya S, Singh RD, Pagano R, Robertson JD, Bhattacharya R, Mukherjee P. Switching the targeting pathways of a therapeutic antibody by nanodesign. Angew Chem Int Ed Engl. 2012 Feb 13; 51(7):1563-7. PMID: 22135077; PMCID: PMC3324088.
    28. Kudgus RA, Bhattacharya R, Mukherjee P. Cancer nanotechnology: emerging role of gold nanoconjugates. Anticancer Agents Med Chem. 2011 Dec; 11(10):965-73. PMID: 21864234.
      View in: PubMed
    29. Bhattacharyya S, Khan JA, Curran GL, Robertson JD, Bhattacharya R, Mukherjee P. Efficient delivery of gold nanoparticles by dual receptor targeting. Adv Mater. 2011 Nov 16; 23(43):5034-8. PMID: 21971980; PMCID: PMC4684084.
    30. Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, Bhattacharya R, Robertson JD, Rotello VM, Reid JM, Mukherjee P. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One. 2011; 6(9):e24374. PMID: 21931696; PMCID: PMC3172229.
    31. Bhattacharyya S, Gonzalez M, Robertson JD, Bhattacharya R, Mukherjee P. A simple synthesis of a targeted drug delivery system with enhanced cytotoxicity. Chem Commun (Camb). 2011 Aug 14; 47(30):8530-2. PMID: 21717027; PMCID: PMC3324332.
    32. Khan JA, Kudgus RA, Szabolcs A, Dutta S, Wang E, Cao S, Curran GL, Shah V, Curley S, Mukhopadhyay D, Robertson JD, Bhattacharya R, Mukherjee P. Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo. PLoS One. 2011; 6(6):e20347. PMID: 21738572; PMCID: PMC3124468.
    33. Wang E, Bhattacharyya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P, Sood AK, Bhattacharya R. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One. 2011 Mar 21; 6(3):e17918. PMID: 21445297; PMCID: PMC3061867.
    34. Arvizo RR, Rana S, Miranda OR, Bhattacharya R, Rotello VM, Mukherjee P. Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine. 2011 Oct; 7(5):580-7. PMID: 21333757.
      View in: PubMed
    35. Patra CR, Jing Y, Xu YH, Bhattacharya R, Mukhopadhyay D, Glockner JF, Wang JP, Mukherjee P. A core-shell nanomaterial with endogenous therapeutic and diagnostic functions. Cancer Nanotechnol. 2010 Dec 01; 1(1):13-18. PMID: 21318050.
      View in: PubMed
    36. Bhattacharyya S, Kudgus RA, Bhattacharya R, Mukherjee P. Inorganic nanoparticles in cancer therapy. Pharm Res. 2011 Feb; 28(2):237-59. PMID: 21104301; PMCID: PMC3072278.
    37. Bhattacharyya S, Bhattacharya R, Curley S, McNiven MA, Mukherjee P. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci U S A. 2010 Aug 17; 107(33):14541-6. PMID: 20679244; PMCID: PMC2930461.
    38. Arvizo RR, Miranda OR, Thompson MA, Pabelick CM, Bhattacharya R, Robertson JD, Rotello VM, Prakash YS, Mukherjee P. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett. 2010 Jul 14; 10(7):2543-8. PMID: 20533851; PMCID: PMC2925219.
    39. Arvizo R, Bhattacharya R, Mukherjee P. Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opin Drug Deliv. 2010 Jun; 7(6):753-63. PMID: 20408736; PMCID: PMC2874072.
    40. Patra CR, Bhattacharya R, Mukherjee P. Fabrication and functional characterization of goldnanoconjugates for potential application in ovarian cancer. J Mater Chem. 2010 Jan 01; 20(3):547-554. PMID: 20436942.
      View in: PubMed
    41. Patra CR, Bhattacharya R, Mukhopadhyay D, Mukherjee P. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev. 2010 Mar 08; 62(3):346-61. PMID: 19914317; PMCID: PMC2827658.
    42. Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, Rossi S, Calin GA, Mukherjee P. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 2009 Dec 01; 69(23):9090-5. PMID: 19903841; PMCID: PMC2859686.
    43. Bhattacharya R, Kwon J, Ali B, Wang E, Patra S, Shridhar V, Mukherjee P. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7659-66. PMID: 19047091.
      View in: PubMed
    44. Basu N, Bhattacharya R, Mukherjee P. Protein-mediated autoreduction of gold salts to gold nanoparticles. Biomed Mater. 2008 Sep; 3(3):034105. PMID: 18689931.
      View in: PubMed
    45. Bhattacharya R, Mukherjee P. Biological properties of "naked" metal nanoparticles. Adv Drug Deliv Rev. 2008 Aug 17; 60(11):1289-306. PMID: 18501989.
      View in: PubMed
    46. Bhattacharya R, Kwon J, Wang E, Mukherjee P, Mukhopadhyay D. Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF Receptor-2 and attenuates endothelial DNA synthesis, but not migration*. J Mol Signal. 2008 Mar 31; 3:8. PMID: 18377662; PMCID: PMC2292718.
    47. Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, Muders M, Wang S, Buhrow SA, Safgren SL, Yaszemski MJ, Reid JM, Ames MM, Mukherjee P, Mukhopadhyay D. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res. 2008 Mar 15; 68(6):1970-8. PMID: 18339879.
      View in: PubMed
    48. Gannon CJ, Patra CR, Bhattacharya R, Mukherjee P, Curley SA. Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells. J Nanobiotechnology. 2008 Jan 30; 6:2. PMID: 18234109; PMCID: PMC2276230.
    49. Curley SA, Cherukuri P, Briggs K, Patra CR, Upton M, Dolson E, Mukherjee P. Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles. J Exp Ther Oncol. 2008; 7(4):313-26. PMID: 19227011.
      View in: PubMed
    50. Patra CR, Bhattacharya R, Patra S, Basu S, Mukherjee P, Mukhopadhyay D. Lanthanide phosphate nanorods as inorganic fluorescent labels in cell biology research. Clin Chem. 2007 Nov; 53(11):2029-31. PMID: 18035595.
      View in: PubMed
    51. Mukherjee P, Bhattacharya R, Bone N, Lee YK, Patra CR, Wang S, Lu L, Secreto C, Banerjee PC, Yaszemski MJ, Kay NE, Mukhopadhyay D. Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. J Nanobiotechnology. 2007 May 08; 5:4. PMID: 17488514; PMCID: PMC1876244.
    52. Patra CR, Bhattacharya R, Patra S, Basu S, Mukherjee P, Mukhopadhyay D. Inorganic phosphate nanorods are a novel fluorescent label in cell biology. J Nanobiotechnology. 2006 Oct 30; 4:11. PMID: 17074086.
      View in: PubMed
    53. Mandal D, Bolander ME, Mukhopadhyay D, Sarkar G, Mukherjee P. The use of microorganisms for the formation of metal nanoparticles and their application. Appl Microbiol Biotechnol. 2006 Jan; 69(5):485-92. PMID: 16317546.
      View in: PubMed
    54. Bhattacharya R, Kang-Decker N, Hughes DA, Mukherjee P, Shah V, McNiven MA, Mukhopadhyay D. Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling. FASEB J. 2005 Oct; 19(12):1692-4. PMID: 16049137.
      View in: PubMed
    55. Bhattacharya R, Senbanerjee S, Lin Z, Mir S, Hamik A, Wang P, Mukherjee P, Mukhopadhyay D, Jain MK. Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2. J Biol Chem. 2005 Aug 12; 280(32):28848-51. PMID: 15980434.
      View in: PubMed
    56. Mukherjee P, Bhattacharya R, Wang P, Wang L, Basu S, Nagy JA, Atala A, Mukhopadhyay D, Soker S. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res. 2005 May 01; 11(9):3530-4. PMID: 15867256.
      View in: PubMed
    57. Ahmad A, Mukherjee P, Mandal D, Senapati S, Khan MI, Kumar R, Sastry M. Enzyme mediated extracellular synthesis of CdS nanoparticles by the fungus, Fusarium oxysporum. J Am Chem Soc. 2002 Oct 16; 124(41):12108-9. PMID: 12371846.
      View in: PubMed
    58. Mukherjee P, Senapati S, Mandal D, Ahmad A, Khan MI, Kumar R, Sastry M. Extracellular synthesis of gold nanoparticles by the fungus Fusarium oxysporum. Chembiochem. 2002 May 03; 3(5):461-3. PMID: 12007181.
      View in: PubMed
    59. Mukherjee P, Ahmad A, Mandal D, Senapati S, Sainkar SR, Khan MI, Ramani R, Parischa R, Ajayakumar PV, Alam M, Sastry M, Kumar R. Bioreduction of AuCl(4)(-) Ions by the Fungus, Verticillium sp. and Surface Trapping of the Gold Nanoparticles Formed D.M. and S.S. thank the Council of Scientific and Industrial Research (CSIR), Government of India, for financial assistance. Angew Chem Int Ed Engl. 2001 Oct 01; 40(19):3585-3588. PMID: 11592189.
      View in: PubMed
    Mukherjee's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description